D-0348-2023 Class II Terminated

Recalled by RISING PHARMACEUTICALS — East Brunswick, NJ

FDA drug recall D-0348-2023 was initiated by RISING PHARMACEUTICALS on Feb 15, 2023 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications The recall status is terminated (terminated Jun 14, 2024). Affected quantity: 12,216 bottles (100 count each).

Recall details

Product Type
Drugs
Report Date
Mar 1, 2023
Initiation Date
Feb 15, 2023
Termination Date
Jun 14, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
12,216 bottles (100 count each)

Product description

Warfarin Sodium Tablets, USP 1 mg, 100-count bottle, Rx Only, Distributed by: Rising Health, LLC, Saddle Brook, NJ 07663, NDC# 57237-119-01

Reason for recall

Failed Impurities/Degradation Specifications

Distribution pattern

Product was distributed to 16 distributors and 8 wholesalers who may have further distributed the product nationwide.

Code information

Batch #: NB101596, Exp. 04/30/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0348-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0348-2023. Report a data issue: hello@regdatalab.com.